Clinical trial · Observational
hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors
Pilot Study of hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors
NCT05157594CI-TRIAL-00095552PROGLIOcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PROGLIO is a French mono-centric study with longitudinal follow-up, in which patients with high grade brain tumors will be included. Blood samples will be taken during their therapeutic follow-up to evaluate plasma concentrations of hPG80 (circulating progastrin).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glial Cell Tumors | Glioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All patients
- description
- A fasting blood sample will be taken on the day of the beginning and the day of the end of the radiotherapy and during the adjuvant chemotherapy (every 3 cycles). A follow-up will be performed for 9 months, with a blood sample taken every three months on the day of the follow-up MRI.
- interventionNames
- Biological: Blood sample
Primary outcomes (1)
- measure
- Plasma concentrations of hPG80
- timeFrame
- From Radiotherapy 1st session to 9 month follow-up
- description
- To evaluate plasma concentrations of hPG80 (circulating progastrin) during therapeutic and recurrence follow-up in patients with high-grade brain tumors.
Secondary outcomes (3)
- measure
- hPG80 concentration according to tumor progression
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female or male 18 years of age or older. * Patients with a high grade primary glial tumor (Astrocytoma grade 3; Glioblastoma; Anaplastic Oligodendroglioma) * Patients scheduled to begin radiation and/or chemotherapy. * Able to give informed consent to participate in the research. * Enrolled in a social security plan or beneficiary of such a plan. Exclusion Criteria: * Patient under guardianship or curatorship * Psychological disorder (cognitive disorders, vigilance disorders, etc.) or social reasons (deprivation of liberty by judicial or administrative decision) or geographical reasons that could compromise the medical follow-up of the trial. * Refusal to participate. * Pregnant or breastfeeding woman.
References
Publications (1)
- DERIVEDCasile M, Passildas J, Vire B, Molnar I, Durando X. hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study. Front Neurol. 2023 Jan 11;13:1073476. doi: 10.3389/fneur.2022.1073476. eCollection 2022. PMID 36712425